All News
Want the highlights of #ACR20 Day 4? Listen to part II of our Day 4 podcast through the link below or through Apple and Android podcasts. Just look up "Rheum Now".
https://t.co/4kJTzISyw2 https://t.co/yATKz886eS
Links:
Dr. John Cush RheumNow ( View Tweet)
We are underdiagnosing this!
In pts with persistently low ALP, think hypophoshatasia (HPP); these pts have recurrent poor healing fractures, may have CPPD, and have been refractory to standard OP Rx.
Dr. A Abelson #ACRReview @rheumnow #ACR20 https://t.co/dVptFkYXR2
k dao KDAO2011 ( View Tweet)
Dr. A Abelson #ACRReview @rheumnow #ACR20
Romosozumab (sclerostin Ab) for OP:
👉can be used after previous treatmt with PTH analogs
👉can be used in pts with prior radiation exposure
👉not yet approved for men.
Some slides on what to choose for OP and when to choose it https://t.co/nAbOmEjx3p
k dao KDAO2011 ( View Tweet)
Dr P Seo notes based on PEXIVAS study while PLEX does not seem to help with AAV, it showed you can drop steroid dose sooner: start pred 1 mg/kg/d but drop down after 1 week to 0.5 mg/kg/d #ACRReview #ACR20 @rheumnow
k dao KDAO2011 ( View Tweet)
Tofa for RA by the grp of Dr. Atul Deodhar:
>Tofa(56%) vs. pbo(29.4%)-significant improvement in ASAS20 at wk 16
>Primary & secondary endpts met
>No new safety signals reported
@Rheumnow #ACR20 https://t.co/G9U5cCQU7K
sheila RHEUMarampa ( View Tweet)
Poll results are in! 76% of you take into account the location of bone marrow edema in the SI joint of patients with inflammatory back pain in trying to determine if a patient has SpA! #ACR20 @RheumNow https://t.co/gwySNvfSH5
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
📌 #ACR20 Checkpoint Inhibitors: Past, Present and Future
👉close surveillance ➡️ early detection of iRAEs➡️ early treatment➡️ reversibility or ⬇️severity
#ACRAmbassador https://t.co/AM2mfYmAtI
Elizabeth Graef SituationRheum ( View Tweet)
And we're off! #ACR20 year in review
⭐️@philseo's #Vasculitis lecture⭐️
Take home lessons/ remaining questions from GiACTA ⬇️
#ACRambassador https://t.co/7C9QxbUeNH
Elizabeth Graef SituationRheum ( View Tweet)
📌More #Vasculitis pearls from #ACR20 Year in Review
#PEXIVAS in a nutshell ⬇️
#ACRambassador https://t.co/PnoP7QIiYs
Elizabeth Graef SituationRheum ( View Tweet)
Pfizer vaccine data potentially shows >90% effectiveness via @nytimes https://t.co/jwVkmbMaTL
Dr Philip Robinson philipcrobinson ( View Tweet)
from #ACR20 Dr. Abbey Abelson. There was reduction in hip fractures in the US until there was drop in reimbursement for DEXA/Bone Density. @ACRheum has been advocating on Capitol Hill to restore reimbursement. Bad policy harms, but good policy can save lives.
#ACRambassador https://t.co/ARo762Vozp
Suleman Bhana, MD DrBhana ( View Tweet)
Thank you Prof Laure Gossec for discussing recent data in Psoriatic Arthritis #ACR20 #ACRambassador https://t.co/f0o8m5K0d2 https://t.co/Wm0sQDUeY1
Links:
Vaneet K Sandhu, MD vksandhumd ( View Tweet)
Some behind the scenes action at #ACR20 #ACRKnowledgeBowl!! More to come tomorrow at 1pm EST with finals! https://t.co/3yLgqqC0Yy
Bharat Kumar BharatKumarMD ( View Tweet)
ARCH study -- n~4100
Romo vs Alendronate x 12 mo
Alendronate 12-24 mo
RRR 38% https://t.co/d0G7x4TqUT
Vaneet K Sandhu, MD vksandhumd ( View Tweet)
Hypophosphatasia
- CPPD/chondrocal, enthesop'y, DISH, exostoses
- DDx of Low ALP: milk-alkali, Vit D intoxic'n, Wilson dz, via C def, celiac dz, adyn renal osteodystrophy, Cushing dz, hypothyroid, major sx, MM
Rx - asfotase alpha- bone targeted replac't Rx
#ACR20 #ACRambassador https://t.co/FJ1355MdKG
Vaneet K Sandhu, MD vksandhumd ( View Tweet)
#ACR20 Abstracts on #ILD
Rituximab in ILD (all observational)
#1053 ➡️ 47 with CTD-ILD: overall improvement or stability at 36m
#1051 ➡️ 50 with IPAF: >70% stable or improved at 12m
#1047 ➡️ 47 patients CTD-ILD or IPAF: good experience with MMF and RTX
#ACRambassador https://t.co/klfVwIH5b6
Sebastian E. Sattui MD, MS SattuiSEMD ( View Tweet)
Over 20,000 tweets and 65 Million+ Impressions Check out the details at https://t.co/Z6X1EeOsnr https://t.co/OtqWZCiu6h
Steven Echard, CAE StevenEchard ( View Tweet)
Latebreaking at #ACR20—Febuxostat was non-inferior to allopurinol with regard to the occurrence of major cardiovascular outcomes in patients with gout: finding from FAST, multicentre, prospective, randomised, open-label, non-inferiority trial https://t.co/cpoNi7zjwi https://t.co/uQyeyepPmj
Links:
The Lancet TheLancet ( View Tweet)
Congrats to Dr @DrDavidKarp on your installation as president of @ACRheum and thanks Dr Ellen Gravallese outgoing president on your outstanding leadership in this year! #ACR20 https://t.co/q0r5URWrEr
Angus Worthing MD AngusWorthing ( View Tweet)
There are a number of important mimics of IgG4-RD that should be considered
🔵ANCA-associated vasculitis
🔵Multicentric Castleman’s disease
🔵Rosai-Dorfman disease
🔵Inflammatory myofibroblastic tumour
🔵Cutaneous plasmacytosis
🔵Erdheim-Chester disease
🔵Malignancy
#ACR20
Chris Wincup chriswincup ( View Tweet)